Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK1
Author for correspondence: Geoffrey L. Smith.Fax +44 1865 275501. e- mail glsmith{at}molbiol.ox.ac.uk
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() |
---|
![]() |
Main text |
---|
![]() ![]() ![]() ![]() |
---|
The mouse is particularly amenable to studies of pathogenesis and immunity because of the availability of well-defined inbred strains, including a growing repertoire of targeted gene knockouts, and a wide range of immunological reagents. Mice can be infected with VV by many routes including intravenous, intraperitoneal, subcutaneous, footpad, intradermal, intracranial and intranasal (Nelson, 1938 ; Briody, 1959
; Turner, 1967
; Buller, 1985
; Andrew et al., 1989
). Intracranial and intranasal inoculation with moderate doses of VV strain Western Reserve (WR) cause severe infections in mice (Turner, 1967
), allowing the relative virulence of virus mutants to be studied. However, the effects of some virus proteins may be too subtle to be detected in the context of these severe infections. Furthermore, severe infections are poor models for vaccination where clinical impact must be minimized. In contrast, mice infected with VV by cutaneous inoculation undergo a limited infection that is well tolerated even at high doses (Briody, 1959
). The outcome of infection with VV mutants by other routes is not always a good predictor of their growth characteristics in skin (Lee et al., 1992
), indicating that virus proteins may exert different effects at different sites of VV infection. Therefore, it seems prudent to investigate the function of VV proteins in a variety of in vivo situations. For these reasons a well-defined cutaneous model of VV infection would be a useful tool for studying the function of VV proteins.
A good model of VV infection should allow many parameters of infection to be assayed including clinical signs, growth of virus, infiltration of lesions and cellular and humoral immune responses. Possible sites for cutaneous inoculation not requiring shaving include the tail, footpad and ear. Tail scarification has been used in many studies but it is difficult to assay virus or to cut histological sections from this site. Infection of the ear pinna causes less distress than footpad inoculation, has been used previously as a model for other virus infections (Hill et al., 1975 ; Moorhead et al., 1999
), and enables straightforward virological and histological analyses. VV has been used to infect mouse ears, but hitherto only virus titres were reported (Ikeda et al., 1991
).
VV strain WR was grown and titrated in RK13 and BS-C-1 cells, respectively. In all experiments, 10 µl containing 10 4, 105 or 106 p.f.u. of VV was injected intradermally into the left ear pinnae of female, adult, BALB/c mice (minimum 8 weeks old) using a 27 gauge needle and a 100 µl Hamilton syringe. Groups of 6 to 12 mice were inoculated and the diameter of surface lesions produced on infected ears was estimated daily to the nearest 0·5 mm using a micrometer ( Fig. 1a and Fig. 2
, row a ). Where mice had more than one lesion an estimate of the total lesion size was made and where lesions were found on both sides of the ear, only the larger was scored. Lesions took 5 days to appear, were maximal between 8 to 10 days post-infection (p.i.) and were resolved by day 22. The size of the lesions correlated well with the inoculation dose and at no time did any mice exhibit signs of generalized infection such as pilo-erection.
|
|
Spread of virus from infected ears was examined by screening homogenates of left cervical draining lymph nodes (DLN), spleen, ovaries and brains for infectious virus. Tissues were taken from each of two mice given 104, 105 and 106 p.f.u. on 4, 8 and 12 days p.i. and the limit of detection was 5 p.f.u. per sample. With the exception of DLN on day 4, no virus was detected outside the ear at any time. The extent of the DLN infection was examined by screening nodes at 2, 4, 6, 9 and 12 days p.i. using the same three doses and three mice per dose on each day. Virus was detectable in DLN of all mice inoculated with 105 and 106 p.f.u. at 2 and 4 days p.i. In contrast, no mice infected with 104 p.f.u. had detectable virus in their DLN on day 2 and only two of three and one of three had virus on days 4 and 6, respectively. All virus titres in DLN were low, the highest being 160 p.f.u. and the mean of all positive results was 20 p.f.u.. These data demonstrate that in this model, doses of up to 106 p.f.u. of VV give an infection that is highly localized.
A histological examination of frozen sections of ears that had been infected with 106 p.f.u. was undertaken at different days p.i. (Fig. 2). A striking feature of infections was the thickening of the ear, best seen in row b. On closer examination (row c) this thickening had two causes: firstly, there was oedema and massive infiltration of the dermis containing CD4 + and CD8+ T lymphocytes, B lymphocytes, macrophages and other leukocytes (not shown); secondly, the epidermis itself was thickened, in some places up to 10 times the normal width, and this was probably due partly to expression of the VV growth factor (Buller et al., 1988
). Measurement of the thickness of ears may provide another marker of the progress of infection and the level of infiltration, but at later times of infection the formation of scabs might distort the accuracy of these measurements. A monoclonal antibody against VV protein B5R (a component of the outer membrane of extracellular enveloped virus) was used to detect infected cells (row d). On day 4 B5R antigen was confined largely to the epidermis but later most of the antigen was seen in round eosinophilic bodies in the middle of the ear. By 12 days p.i. B5R antigen was very scarce and was absent from 20 days p.i.
To analyse the host response to infection, VV-specific CD4+ and CD8+ T cells and antibody responses were measured. Cellular immunity to VV was assessed by the measurement of VV- specific, interferon- (IFN-
)-secreting cells using a new ELISPOT technique. In published ELISPOT methods (Miyahira et al ., 1995
), T cells are stimulated by addition of peptide; however, as yet no T cell epitopes have been defined for VV. Nonetheless, we found that either UV/trioxsalen-inactivated intracellular mature vaccinia virus (IMV) (Hanson et al., 1978
), equivalent originally to 106 to 107 p.f.u. per well, or P815 cells 4 to 8 h p.i. with VV (10 p.f.u. per cell) and
-irradiated (3000 rads) at 105 cells per well, were able to stimulate IFN-
production by splenocytes from VV-infected but not uninfected mice. Further, by using monoclonal antibodies and complement to deplete splenocyte suspensions of T cell subsets, it was apparent that whereas UV/trioxsalen- inactivated VV stimulated only CD4+ T cells, VV-infected P815 cells stimulated only CD8+ T cells (data not shown). To ensure that the IFN-
release was VV-specific, either extracts purified from uninfected cells and then treated with UV/trioxsalen as for inactivation of virus, or uninfected P815 were used as negative control antigens. All other reagents and conditions were as published (Schneider et al., 1998
).
The ELISPOT technique was used to measure CD4+ and CD8 + T cell responses in groups of three mice (Fig. 3 a and b
, respectively). Mice inoculated with 104, 10 5 and 106 p.f.u. of VV had similar numbers of VV- specific CD4+ T cells in their spleens at all times tested and the same was true for CD8+ T cells. T cell responses were maximal during the peak of infection reflecting the large number of effector cells generated to clear the acute infection. Spleens were also enlarged visibly at these times and often had twice as many cells as spleens from uninfected controls. In this experiment, memory responses declined slightly from 24 to 49 days p.i. but in other experiments, VV-specific IFN-
secreting T cells have been found to be maintained at 30/106 splenocytes at 75 days p.i.
|
In conclusion, we report the characterization of a cutaneous model of VV infection that allows many facets of pathogenesis and immunity to be examined. Intradermal inoculation of ears with VV causes far less distress to the mice than intracranial and intranasal models but as with other cutaneous models, is sensitive to virus dose and genotype (Briody, 1959 ; Buller, 1985
; Lee et al., 1992
) (our unpublished results). In addition, the ear infection is highly localized to the site of inoculation while stimulating cellular and humoral immune responses, providing a good model for vaccination.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() |
---|
Antoine, G. , Scheiflinger, F. , Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.[Medline]
Blanchard, T. J. , Alcamí, A. , Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Journal of General Virology 79, 1159-1167 .[Abstract]
Briody, B. (1959). Response of mice to ectromelia and vaccinia viruses. Bacteriological Reviews 23, 61-95.[Medline]
Buller, R. M. (1985). The BALB/c mouse as a model to study orthopoxviruses. Current Topics in Microbiology and Immunology 122, 148-153.[Medline]
Buller, R. M. , Chakrabarti, S. , Moss, B. & Fredrickson, T. (1988). Cell proliferative response to vaccinia virus is mediated by VGF. Virology 164, 182-192.[Medline]
Hanson, C. V. , Riggs, J. L. & Lennette, E. H. (1978). Photochemical inactivation of DNA and RNA viruses by psoralen derivatives. Journal of General Virology 40, 345-358.[Abstract]
Hill, T. J. , Field, H. J. & Blyth, W. A. (1975). Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28, 341-353.[Abstract]
Ikeda, S. , Tominaga, T. & Nishimura, C. (1991). Thy 1+ asialo GM1+ dendritic epidermal cells in skin defense mechanisms of vaccinia virus-infected mice. Archives of Virology 117, 207-218.[Medline]
Lee, M. S. , Roos, J. M. , McGuigan, L. C. , Smith, K. A. , Cormier, N. , Cohen, L. K. , Roberts, B. E. & Payne, L. G. (1992). Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Journal of Virology 66, 2617-2630 .[Abstract]
Miyahira, Y. , Murata, K. , Rodriguez, D. , Rodriguez, J. R. , Esteban, M. , Rodrigues, M. M. & Zavala, F. (1995). Quantification of antigen specific CD8+ T cells using an ELISPOT assay. Journal of Immunological Methods 181, 45-54.[Medline]
Moorhead, J. W. , Clayton, G. H. , Smith, R. L. & Schaack, J. (1999). A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. Journal of Virology 73, 1046-1053 .
Nelson, J. B. (1938). The behaviour of poxviruses in the respiratory tract. I. The response of mice to the nasal instillation of vaccinia virus. Journal of Experimental Medicine 68, 401-412.
Schneider, J. , Gilbert, S. C. , Blanchard, T. J. , Hanke, T. , Robson, K. J. , Hannan, C. M. , Becker, M. , Sinden, R. , Smith, G. L. & Hill, A. V. (1998). Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine 4, 397-402.[Medline]
Smith, G. L. , Symons, J. A. , Khanna, A. , Vanderplasschen, A. & Alcamí, A. (1997). Vaccinia virus immune evasion. Immunological Reviews 159, 137-154.[Medline]
Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J. C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B., Riviere, M. and others (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217232.[Medline]
Turner, G. S. (1967). Respiratory infection of mice with vaccinia virus. Journal of General Virology 1, 399-402.[Medline]
Received 29 April 1999;
accepted 9 June 1999.